Stock Analiz

Macrogenics Inc. MGNX

Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026

$2.20Market cap $141M
Open the interactive analysis →

Macrogenics Inc. (MGNX) is a healthcare company listed in the US with a market value of about $141M. In the twelve months to September 30, 2026 it had revenue of $141M and net income of -$51M, a net margin of -36.6%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 7% a year, a 5-year average ROIC of -71%.

About Macrogenics

Macrogenics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $48M in 2014 to $150M in 2025, growth of about 10.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 98% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.0
P/B5.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-29.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-0.3%
Revenue growth (5 yrs, per year)7.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-90.0%
ROIC (5-yr avg.)-70.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$141M$150M$150M$59M$152M$77M$105M$64M$60M$158M$92M
Net income-$51M-$75M-$67M-$9M-$120M-$202M-$130M-$152M-$171M-$20M-$59M
Free cash flow-$41M-$83M-$72M-$80M-$91M-$150M-$118M-$139M-$178M-$15M-$55M
EPS (diluted)$-0.81$-1.18$-1.07$-0.15$-1.95$-3.37$-2.47$-0.62$-1.06$-0.54$-1.00
Net margin-36.6%-49.9%-44.7%-15.4%-78.8%-261.0%-123.7%-236.5%-285.2%-12.4%-63.7%
ROIC—-78.2%-56.9%-90.2%-68.7%-60.4%-31.8%-53.6%-50.0%-5.9%-17.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $8.00, 264% above the current price; targets range from $4.00 to $11.00; the consensus rating is “Buy”; expected EPS is $-2.47 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Macrogenics pay a dividend?

Not currently.

Is Macrogenics a good stock to buy?

We do not give buy or sell advice. Macrogenics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.